Valneva has partnered with LimmaTech Biologics to acquire exclusive rights to develop and market Shigella4V, a vaccine candidate against shigellosis. The agreement includes an upfront payment...
The agreement between the two companies allows Debiopharm to access licensing options to continue the development of SunRock Biopharma's antibodies, integrating Debiopharm's innovative conjugation technologies, called...